Interaction Between Dipeptidyl-peptidase-4 Inhibitors and Drugs Acting on Renin Angiotensin Aldosterone System for the Risk of Angioedema: a Pharmacovigilance Assessment Using Disproportionality and Interaction Analyses

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2025 Jan 8

PMID 39773243

Authors

Kannan Sridharan

Gowri Sivaramakrishnan

Affiliations

Soon will be listed here.

Abstract

Background: Dipeptidyl peptidase-4 inhibitors (DPP-4is) and drugs interfering with the renin-angiotensin-aldosterone system (RAAS) are frequently co-prescribed in type 2 diabetes management. Both drug classes have been independently associated with angioedema, raising concerns about potential interaction risks. This study aimed to evaluate the safety signals and interaction patterns for angioedema associated with DPP-4is alone and in combination with RAAS-interfering drugs.

Methods: We conducted a comprehensive pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database. Disproportionality analyses employing both frequentist (Reporting Odds Ratio, Proportional Reporting Ratio) and Bayesian approaches were performed. Drug-drug interactions were assessed using multiplicative drug-drug interaction model. Additionally, we reviewed published case reports of DPP-4i-associated angioedema.

Results: Analysis of 29,163,222 reports identified 588 cases of DPP-4i-associated angioedema. Significant safety signals were detected for DPP-4i monotherapies, while combinations with RAAS-interfering drugs demonstrated stronger signals through both frequentist and Bayesian analyses. Significant interaction signals were observed for sitagliptin/irbesartan, sitagliptin/valsartan, linagliptin/valsartan and alogliptin/lisinopril combinations. Alogliptin/lisinopril and sitagliptin/irbesartan combinations showed the highest risk profiles. Angioedema occurred predominantly in elderly patients (> 65 years) and females. Sixteen case reports corroborated the findings from the database assessment. Clinical outcomes were comparable between monotherapy and combination therapy groups.

Conclusion: This pharmacovigilance analysis reveals significant safety signals for angioedema with specific DPP-4i combinations with RAAS-interfering drugs, suggesting potential drug-drug interactions. These findings emphasize the need for careful patient monitoring, particularly in vulnerable populations, when prescribing these combinations. Further prospective studies are warranted to validate these findings and establish definitive causal relationships.

References

Faillie J . Case-non-case studies: Principle, methods, bias and interpretation. Therapie. 2019; 74(2):225-232. DOI: 10.1016/j.therap.2019.01.006. View

Win T, Chaiyakunapruk N, Suwankesawong W, Dilokthornsakul P, Nathisuwan S . Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database. Asian Pac J Allergy Immunol. 2015; 33(3):227-35. DOI: 10.12932/AP0556.33.3.2015. View

Ohyama K, Shindo J, Takahashi T, Takeuchi H, Hori Y . Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS). Sci Rep. 2022; 12(1):13122. PMC: 9338932. DOI: 10.1038/s41598-022-17366-x. View

Yeddi A, Abdelhai M, Mohamed A, Yeddi O, Salih L, Ali M . Alogliptin-Associated Angioedema: Case Report and Review of the Literature. Am J Ther. 2020; 29(6):e748-e749. DOI: 10.1097/MJT.0000000000001214. View

Millot I, Plancade D, Hosotte M, Landy C, Nadaud J, Ragot C . Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. Br J Anaesth. 2012; 109(5):827-9. DOI: 10.1093/bja/aes371. View

Sridharan K, Sivaramakrishnan G . A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2024; :1-8. DOI: 10.1080/14740338.2024.2393279. View

Hamasaki H, Yanai H . The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013; 168(3):e106. DOI: 10.1016/j.ijcard.2013.07.257. View

Capuano A, Sportiello L, Maiorino M, Rossi F, Giugliano D, Esposito K . Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther. 2013; 7:989-1001. PMC: 3782406. DOI: 10.2147/DDDT.S37647. View

Noguchi Y, Murayama A, Esaki H, Sugioka M, Koyama A, Tachi T . Angioedema Caused by Drugs That Prevent the Degradation of Vasoactive Peptides: A Pharmacovigilance Database Study. J Clin Med. 2021; 10(23). PMC: 8658484. DOI: 10.3390/jcm10235507. View

10.

Loftus P, Tan M, Patel G, Lin J, Helman S, Badhey A . Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors. Laryngoscope. 2014; 124(11):2502-7. DOI: 10.1002/lary.24777. View

11.

Noguchi Y, Tachi T, Teramachi H . Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 2021; 22(6). DOI: 10.1093/bib/bbab347. View

12.

Gabb G, Andrew N . Lump in the throat - a case study. Aust Fam Physician. 2013; 42(12):863-6. View

13.

Byrd J, Minor D, Elsayed R, Marshall G . DPP-4 inhibitors and angioedema: a cause for concern?. Ann Allergy Asthma Immunol. 2011; 106(5):436-8. DOI: 10.1016/j.anai.2011.02.012. View

14.

Goedhart J, Luijsterburg M . VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci Rep. 2020; 10(1):20560. PMC: 7689420. DOI: 10.1038/s41598-020-76603-3. View

15.

Fusaroli M, Salvo F, Begaud B, Alshammari T, Bate A, Battini V . The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf. 2024; 47(6):585-599. PMC: 11116264. DOI: 10.1007/s40264-024-01423-7. View

16.

Montastruc J, Sommet A, Bagheri H, Lapeyre-Mestre M . Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011; 72(6):905-8. PMC: 3244636. DOI: 10.1111/j.1365-2125.2011.04037.x. View

17.

Nandikanti D, Gosmanova E, Gosmanov A . Acute Kidney Injury Associated with Linagliptin. Case Rep Endocrinol. 2016; 2016:5695641. PMC: 4769737. DOI: 10.1155/2016/5695641. View

18.

Abouelkheir M, El-Metwally T . Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. Eur J Pharmacol. 2019; 862:172638. DOI: 10.1016/j.ejphar.2019.172638. View

19.

Schneider A, Ramesh M . Angioedema following initiation of glecaprevir/pibrentasvir while on sitagliptin. J Allergy Clin Immunol Pract. 2019; 7(6):2068-2069. DOI: 10.1016/j.jaip.2019.02.008. View

20.

Ejikeme C, Nwachukwu C, Viechweg J, Ejikeme I, Brescia M . DPP-IV Inhibitor-Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema. J Investig Med High Impact Case Rep. 2021; 9:23247096211033049. PMC: 8326613. DOI: 10.1177/23247096211033049. View